Skye Bioscience (SKYE) Chief Scientific Officer receives 150,000 stock options at $0.82

Rhea-AI Filing Summary

Skye Bioscience Chief Scientific Officer granted 150,000 stock options. Christopher Twitty received a stock option for 150,000 shares of common stock at an exercise price of $0.82 per share on February 6, 2026. All 150,000 options are held directly.

The option vests in equal monthly installments over a four-year period beginning January 19, 2026, meaning portions become exercisable each month over that timeframe rather than all at once.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Twitty Christopher

(Last) (First) (Middle)

11250 EL CAMINO REAL, SUITE 100

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		150,000		(1)	02/06/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Skye Bioscience (SKYE) disclose about Christopher Twitty in this Form 4?

The filing shows Christopher Twitty, Chief Scientific Officer of Skye Bioscience, received a stock option for 150,000 shares of common stock. These derivative securities are held directly and were granted as part of his equity compensation.

How many Skye Bioscience (SKYE) stock options were granted to the Chief Scientific Officer?

The Chief Scientific Officer received a grant of 150,000 stock options. Each option represents the right to buy one share of Skye Bioscience common stock, giving him potential future ownership of 150,000 shares if the options are exercised.

What is the exercise price of the Skye Bioscience (SKYE) stock options granted?

The stock options carry an exercise price of $0.82 per share. This means Christopher Twitty can purchase Skye Bioscience common stock at $0.82 for each option that becomes vested and is later exercised, regardless of future market prices.

When do the Skye Bioscience (SKYE) stock options begin vesting and over what period?

The stock option begins vesting on January 19, 2026, in equal monthly installments over a four-year period. This structure gradually makes portions of the 150,000 options exercisable each month instead of all at once.

How many Skye Bioscience (SKYE) derivative securities does Christopher Twitty own after this transaction?

After the reported transaction, Christopher Twitty beneficially owns 150,000 derivative securities in the form of stock options. All of these options are reported as held in a direct ownership capacity, with no indirect ownership entity disclosed.

What transaction code was used for the Skye Bioscience (SKYE) stock option grant?

The transaction is reported with code "A", indicating an acquisition of derivative securities. In this case, it reflects the initial grant of 150,000 stock options to the Chief Scientific Officer at an exercise price of $0.82 per share.